Platelet function and myocardial injury during percutaneous coronary intervention

Journal of Thrombosis and Thrombolysis

Volumn 13, Issue 2, 2002, Pages 69-73

  Saleh, N ^a   Hansson, L O ^a   Kohut, M ^a   Nilsson, T ^a   Tornvall, P ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Glycoprotein IIb IIIa inhibitor; Myocardial injury; Percutaneous coronary intervention; Platelet function

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; LONG ACTING DRUG; NITRATE; TROPONIN T; BIOLOGICAL MARKER; TROPONIN I;

ADULT; AGED; ANGINA PECTORIS; ARTERIAL BLOOD; ARTICLE; BLOOD CLOTTING TIME; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE ACTIVITY; FEMALE; FLOW CYTOMETRY; HEART INFARCTION; HEART MUSCLE INJURY; HIGH RISK PATIENT; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEPTOR BLOCKING; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; TRANSLUMINAL CORONARY ANGIOPLASTY; BLOOD; BLOOD CLOTTING PARAMETERS; EVALUATION; HEART SURGERY; HOSPITAL INFORMATION SYSTEM; INSTRUMENTATION; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PEROPERATIVE CARE;

AGED; ANGINA PECTORIS; ASPIRIN; BIOLOGICAL MARKERS; CARDIAC SURGICAL PROCEDURES; FEMALE; HUMANS; INTRAOPERATIVE CARE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET ACTIVATION; PLATELET FUNCTION TESTS; POINT-OF-CARE SYSTEMS; TROPONIN I;

EID: 0036056948     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016238612418     Document Type: Article

References (17)

1. Whole blood impedance platelet aggregometry and ischemic heart disease. The Caerphilly collaborative heart disease study
2. Blood platelet count and function are related to total and cardiovascular death in apparantly healthy men
3. Platelet hyperreactivity and prognosis in survivors of myocardial infarction
4. Platelet reactivity in unstable coronary artery disease
5. Can the risk for acute cardiac events in acute coronary syndrome be indicated by platelet membrane activation marker P-selectin?
6. Collaborative overview of randomised trials of antiplatelet therapy-I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
7. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease
8. Performance of the platelet function analyser PFA-100® in testing abnormalities of primary haemostasis
9. Description of an in vitro platelet function analyzer - PFA-100®
10. Use of the PFA-100 apparatus to assess platelet function in patients undergoing PTCA during and after infusion of cE3 Fab in the presence of other antiplatelet agents
11. Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA
12. Platelet reactivity characterized prospectively
13. Benefit of abciximab in patients with refractory unstable angina pectoris in relation to serum troponin T levels
14. Platelet activation and inhibition in unstable coronary syndromes
15. Platelet function analysis with PFA-100 in patients medicated with acetylsalicyclic acid strongly depends on concentration of sodium citrate used for anticoagulation of blood sample
16. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100
17. Myonecrosis after revascularization procedures